Transaction · 0001193125-26-381853

Crystal Adam

Crystal Adam, PRES, R, D, reported an open-market or private sale at Tango Therapeutics, Inc. involving 27000.000000 shares for an estimated $603909.00. Reported holdings after the transaction were 115743.000000 shares. The stored filing text includes a detected 10b5-1 reference.

Open-market sellSEC transaction code SPRES, R, D
TNGXTango Therapeutics, Inc.
Filing timeSep 03
Trade dateSep 01, 2026
Filing · SECView on SEC
InsiderProfile

Price performance since filing

Close on the filing date, the pre-filing context, and the forward return at standard windows
Price at filing
$24.70
Pre-filing
1mo ago +10.0%1w ago +0.0%1d ago +0.0%
Returns since
7d +0.0%30d +0.0%90d +0.0%180d +0.0%1y +0.0%

TNGX price since this filing

30 days of pre-filing context and vertical markers at the filing date plus 7d / 30d / 90d / 180d / 1y afterwards
TNGX since 2026-09-03Filed today · pre-filing context shaded
Loading…
Filing datePost-filing windows (7d, 30d, 90d, 180d, 1y)30 days of pre-filing context

Transaction facts

Stored Form 4 columns with their raw values

Non-derivative
Type
Sell
Code S
Identifier
0001193125-26-381853
Common Stock
Transaction date
Sep 01, 2026
Filed Sep 03, 2026, 08:01 PM · 2d delay
Shares
27.0k sh
$2.23k per share
Estimated value
-$60.3M
Computed from shares × price
Holdings after
115k sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $10.0MLarge $100M
Direct Ownership Large Sale 10b5-1 Detected
0score
Filing-only score

0

Compact filing score computed from stored Form 4 facts. Version v1.

Neutral filing signal

This filing is broadly neutral on the filing-only scale. The Form 4 facts do not strongly tilt positive or negative.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

President, R&D

Officer YesDirector No10% NoOther No
Footnotes & amended
  1. F1

    These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025.

  2. F2

    Represents the weighted average sales price per share. The shares sold at prices ranging from $22.08 to $22.86 per share. Full information regarding the number of shares sold at each price shall be pr…

  3. F3

    This option shall vest and become exercisable over a four-year period, at a rate of 25% on February 27, 2024, with the remaining option shares vesting in 36 equal monthly installments thereafter.

Original filing · 0001193125-26-381853
Related transactions

0 other filings

Same reporting owner
Recent company activity

0 recent txs

TNGX